Urol. praxi. 2019;20(1):13-18 | DOI: 10.36290/uro.2019.041

Pharmacological prophylaxis of bleeding in urological procedures

MUDr. Michal Balík, MUDr. Jaroslav Pacovský, Ph.D.
Urologická klinika LF a FN v Hradci Králové

The rising number of urological procedures and the increasing age and morbidity of urologic patients increase the risk of perioperative
bleeding complications. There is no simple recommendation to prevent bleeding. It should be based on the current state
of the patient, who undergo the specific urological procedure. Often, consultation with a specialist (hematologist or angiologist)
is useful. In this paper we present an overview of the current possibilities of pharmacological prophylaxis of bleeding during
urological procedures.

Keywords: pharmacologic, prophylaxis, bleeding, urology

Published: March 18, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Balík M, Pacovský J. Pharmacological prophylaxis of bleeding in urological procedures. Urol. praxi. 2019;20(1):13-18. doi: 10.36290/uro.2019.041.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kozek-Langenecker SA, Afshari A, Albaladejo P, Santullano CA, De Robertis E, et al. Management of severe perioperative bleeding: guidelines fromthe European Society of Anaesthesiology. Eur JAnaesthesiol. 2013; 30: 270-382. Go to original source... Go to PubMed...
    2. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006; 114(8): 774-782. Go to original source... Go to PubMed...
    3. Rogers MA, Blumberg N, Heal JM, Hicks GL Jr. Increased risk of infection and mortality in women after cardiac surgery ated to allogeneic blood transfusion. J Womens Health (Larchmt). 2007; 16(10): 1412-1420. Go to original source... Go to PubMed...
    4. Linder BJ, Frank I, Cheville JC, et al. The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy. Eur Urol. 2013; 63: 839-845. Go to original source... Go to PubMed...
    5. Wang YL, Jiang B, Yin FF, et al. Perioperative blood transfusion promotes worse outcomes of bladder cancer after radical cystectomy: a systematic review and meta-analysis. Su Z, ed. PLoS ONE. 2015. Go to original source...
    6. Douketis JD, Spyropoulos AC, Spencer FA, et al. American College of Chest Surgeons. Perioperative management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [erratum appears in Chest. 2012; 141(4): 1129]. Chest. 2012; 141(Suppl 2): 326-350. Go to original source...
    7. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001 Jun 13; 285(22): 2864-2870. Go to original source... Go to PubMed...
    8. Pisters R, Lane DA, Nieuwelaat R, et al. A novel, user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey. Chest 2010; 138: 1093-1100. Go to original source... Go to PubMed...
    9. Orsini S, Noris P, Bury L, Heller PG, et al. Bleeding risk of surgery and its prevention in patients with inherited platelet disorders. Haematologica. 2017 Jul; 102(7): 1192-1203. Go to original source... Go to PubMed...
    10. Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia 2013; 19: 1. Go to original source... Go to PubMed...
    11. Hermans C, Altisent C, Batorova A, et al. Replacement therapy for invasive procedures in patients with haemophilia: literature review, European survey and recommendations. Haemophilia 2009; 15: 639. Go to original source... Go to PubMed...
    12. Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood 2004; 104: 1243-1252. Go to original source... Go to PubMed...
    13. Castaman G. Prophylaxis of bleeding episodes and surgical interventions in patients with rare inherited coagulation disorders. Blood Transfus; 8(Suppl 2): 39-44.
    14. Ng VL. Liver disease, coagulation testing and heamostasis. Clinics in Laboratory Medicine, 2009; 29(2): 265-282. Go to original source... Go to PubMed...
    15. Lisman T, Caldwell SH, Burroughs AK, et al. Hemostasis and thrombosis in patients with liver disease: the ups and downs. Journal of Hepatology 2010; 53(2): 362-371. Go to original source... Go to PubMed...
    16. Amarapurkar PD, Amarapurkar DN. Management of Coagulopathy in Patients with Decompensated Liver Cirrhosis. Int J Hepatol. 2011; 2011: 695470. Go to original source... Go to PubMed...
    17. Belej K. Léky ovlivňující koagulaci v urologii. Urol. Praxi, 2008; 9(2): 64-68.
    18. Heinc P, Táborský M, Kováčik F, Lazárová M, Přeček J. Perioperační riziko v éře nových antikoagulancií. Urol. Praxi, 2013; 14(2): 77-80.
    19. Ortel T. Perioperative management of patients on chronic antithrombotic therapy. Hematology Am Soc Hematol Educ Program. 2012; 2012: 529-535. Go to original source... Go to PubMed...
    20. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015. Go to original source... Go to PubMed...
    21. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057. Go to original source... Go to PubMed...
    22. Garcia DA, Regan S, Henault LE, et al. Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med. 2008; 168(1): 63-69. Go to original source... Go to PubMed...
    23. Kovacs MJ, Kearon C, Rodger M, et al. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation 2004; 110(12): 1658-1663. Go to original source... Go to PubMed...
    24. Douketis JD. Perioperative management of patients who are receiving warfarin therapy: an evidence-based and practical approach. Blood. 2011; 117(19): 5044-5049. Go to original source... Go to PubMed...
    25. Schulman S, Crowther MA. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood. 2012; 119(13): 3016-3023. Go to original source... Go to PubMed...
    26. Hu TY, Vaidya VR, Asirvatham SJ. Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab. Vasc Health Risk Manag. 2016; 12: 35-44. Go to original source... Go to PubMed...
    27. Karetová D, Bultas J. Řešení urgentních stavů spojených s rizikem krvácení u nemocných užívajících nová perorální antikoagulancia - možnosti ukončení účinku. Remedia 2016; 26: 135-140.
    28. Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med. 2010; 363(19): 1791-1800. Go to original source... Go to PubMed...
    29. Schulman S. Pharmacologic tools to reduce bleeding in surgery. Hematology Am Soc Hematol Educ Program. 2012; 2012: 517-521. Go to original source... Go to PubMed...
    30. Carless PA, Henry DA, Moxey AJ, et al. Desmopressin for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 2004; 1: CD001884. Go to original source... Go to PubMed...
    31. Karlsson M, Ternstrom L, Hyllner M, et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery. A prospective randomised pilot study. Thromb Haemost. 2009; 102(1): 137-144. Go to original source... Go to PubMed...
    32. Sadeghi M, Atefyekta R, Azimaraghi O, et al. A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery. Braz J Anesthesiol. 2014 Jul-Aug; 64(4): 253-257. Go to original source... Go to PubMed...
    33. Fergusson DA, Hébert PC, Mazer CD, Fremes S, MacAdams C, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med. 2008; 358(22): 2319-2331. Go to original source... Go to PubMed...
    34. Erstad BL. Systemic hemostatic medications for reducing surgical blood loss. Ann Pharmacother 2001; 35: 925-934. Go to original source... Go to PubMed...
    35. Dunn CJ, Goa KL. Tranexamic acid: a review of its use in surgery and other indications. Drugs 1999; 57: 1005-1032. Go to original source... Go to PubMed...
    36. McCormack PL. Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis. Drugs 2012; 72: 585-617. Go to original source... Go to PubMed...
    37. Benoni G, Lethagen S, Nilsson P, Fredin H. Tranexamic acid, given at the end of the operation, does not reduce postoperative blood loss in hip arthroplasty. Acta Orthop. Scand. 2000; 71: 250-254. Go to original source... Go to PubMed...
    38. Nielsen JD, Gram J, Fabrin A, et al. Lack of correlation between blood fibrinolysis and the immediate or post-operative blood loss in transurethral resection of the prostate. Br J Urol 1997; 80: 105-110. Go to original source... Go to PubMed...
    39. Madsen PO, Strauch AE. The effect of aminocaproic acid on bleeding following transurethral prostatectomy. J Urol 1966; 96: 255-256. Go to original source...
    40. Sharifi R, Lee M, Ray P, et al. Safety and efficacy of intravesical aminocaproic acid for bleeding after transurethral resection of prostate. Urology 1986; 27: 214-219. Go to original source... Go to PubMed...
    41. Casati V, Guzzon D, Oppizzi M, Cossolini M, Torri G, Calori G, Afieri O. Hemostatic effects of aprotinin, tranexamic acid and epsilon-aminocaproic acid in primary cardiac surgery. Ann. Thorac. Surg. 1999; 68: 2252-2256; discussion 2256-2257. Go to original source... Go to PubMed...
    42. Fergusson DA, Hebert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N. Engl. J. Med. 2008; 358: 2319-2331. Go to original source... Go to PubMed...
    43. Claeys MA, Vermeersch N, Haentjens P. Reduction of blood loss with tranexamic acid in primary total hip replacement surgery. Acta Chir. Belg. 2007; 107: 397-401. Go to original source... Go to PubMed...
    44. Rannikko A, Pétas A, Taari K. Tranexamic acid in control of primary hemorrhage during transurethral prostatectomy. Urology. 2004. Go to original source...
    45. Kumsar S, et al. Tranexamic Acid Decreases Blood Loss during Transurethral Resection of the Prostate (TUR-P). Central European Journal of Urology 64.3 2011: 156-158. Go to original source... Go to PubMed...
    46. Pourfakhr P, Gatavi E, Gooran S, et al. Local Administration of Tranexamic Acid During Prostatectomy Surgery: Effects on Reducing the Amount of Bleeding. Nephrourol Mon. 2016 Aug 23. Go to original source... Go to PubMed...
    47. Zaid HB, Yang DY, Tollefson MK, et al. Efficacy and Safety of Intraoperative Tranexamic Acid Infusion for Reducing Blood Transfusion During Open Radical Cystectomy. Urology. 2016 Jun; 92: 57-62. Go to original source... Go to PubMed...
    48. Montroy J, Fergusson NA, Hutton B, et al. The Safety and Efficacy of Lysine Analogues in Cancer Patients: A Systematic Review and Meta-Analysis. Transfus Med Rev. 2017 Jul; 31(3): 141-148. Go to original source... Go to PubMed...
    49. Pabinger I, Fries D, Schöschl H, Streif W, Toller W. Tranexamic acid for treatment and profylaxis of bleeding and hyperfibrinolys. Wien Klin Wochenschr 2017; 129: 303-316. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.